Govindan R, et al. Phase 1 study of safety, tolerability, PK and efficacy of AMG 510, a novel KRAS G12Cinhibitor, evaluated in NSCLC. Abstract OA02.02. WCLC 2019, 7-10 september, Barcelona, Spanje.
'We hebben echt wel wat waar te maken'
jul 2018
feb 2024 | Longoncologie
dec 2023 | Uro-oncologie
dec 2022 | Maag-darm-leveroncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie
sep 2024
jul 2024
jun 2024
mrt 2024